^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
PGR positive
i
Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1d
NORDIS: Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (clinicaltrials.gov)
P=N/A, N=50, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • PGR positive
1d
POSITIVE: Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (clinicaltrials.gov)
P=N/A, N=518, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial primary completion date: Dec 2025 --> May 2025
Trial primary completion date
|
PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
BRCA2 mutation • BRCA1 mutation • PGR positive
4d
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging (clinicaltrials.gov)
P1/2, N=0, Withdrawn, University of Alabama at Birmingham | N=20 --> 0 | Recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 positive • PGR positive
7d
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (clinicaltrials.gov)
P3, N=1670, Recruiting, NRG Oncology | Trial primary completion date: Jan 2026 --> Apr 2026
Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR positive
|
MammaPrint® • Oncotype DX Breast Recurrence Score®Test
|
tamoxifen • letrozole • exemestane
7d
Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype (clinicaltrials.gov)
P3, N=248, Not yet recruiting, Fudan University
New P3 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression • PGR positive
|
trastuzumab rezetecan (SHR-A1811) • famitinib (SHR 1020)
9d
A Case of Invasive Ductal Carcinoma with Axillary Skip Metastasis Confined to the Interpectoral (Rotter's) Lymph Node. (PubMed, Surg Case Rep)
This extraordinarily rare case of axillary skip metastasis limited to the interpectoral node emphasizes the potential for false-negative SN biopsies. Careful review of preoperative images, particularly MRI images, is crucial to avoid understaging. Awareness of interpectoral node involvement may help guide appropriate treatment strategies for selected patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
11d
Treatment pattern and preferences of locally advanced and metastatic HR+, HER2- breast cancer from a Chinese physician and patient survey (ChiCTR2600116892)
P=N/A, N=320, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
New trial
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR positive
11d
Longitudinal Changes in the Vaginal Microbiome During Endocrine Therapy in Premenopausal Breast Cancer and Their Association with Genitourinary Syndrome of Menopause (GSM): A Single-Center Prospective Cohort Study. (ChiCTR2500115283)
P=N/A, N=110, Not yet recruiting, Women's Hospital School of Medicine Zhejiang University; Women's Hospital School of Medicine Zhejiang University
New trial
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PGR positive
11d
Efficacy and safety of Dalpiciclib in the treatment of hormone receptor-positive advanced breast cancer a multicenter observational real-world study (ChiCTR2500114023)
P=N/A, N=500, Recruiting, Harbin Medical University Affiliated Cancer Hospital; Harbin Medical University Affiliated Cancer Hospital
New trial
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • PGR positive
|
AiRuiKang (dalpiciclib)
11d
A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer (ChiCTR2500111780)
P4, N=148, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
New P4 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
|
paclitaxel • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin • goserelin acetate
18d
TBCRC 050: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer (clinicaltrials.gov)
P1/2, N=46, Active, not recruiting, University of Alabama at Birmingham | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Nov 2026 --> Nov 2027
Trial completion date • Trial primary completion date
|
PGR (Progesterone receptor)
|
PGR positive • EGFR positive
|
Herceptin (trastuzumab) • Zejula (niraparib)
19d
REaCT-HER TIME: Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy (clinicaltrials.gov)
P4, N=52, Active, not recruiting, Ottawa Hospital Research Institute | Recruiting --> Active, not recruiting
Enrollment closed
|
PGR (Progesterone receptor)
|
HER-2 positive • PGR positive
|
Herceptin (trastuzumab)
Share via
